1. Home
  2. ADM vs ALNY Comparison

ADM vs ALNY Comparison

Compare ADM & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer-Daniels-Midland Company

ADM

Archer-Daniels-Midland Company

HOLD

Current Price

$84.55

Market Cap

38.6B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$264.37

Market Cap

38.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADM
ALNY
Founded
1902
2002
Country
United States
United States
Employees
N/A
115
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.6B
38.9B
IPO Year
2008
2004

Fundamental Metrics

Financial Performance
Metric
ADM
ALNY
Price
$84.55
$264.37
Analyst Decision
Hold
Strong Buy
Analyst Count
6
28
Target Price
$64.00
$471.00
AVG Volume (30 Days)
3.3M
1.6M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
2.80%
N/A
EPS Growth
N/A
206.88
EPS
2.49
2.71
Revenue
$80,269,000,000.00
$1,037,418,000.00
Revenue This Year
$4.80
$52.67
Revenue Next Year
$2.77
$31.48
P/E Ratio
$33.51
$96.79
Revenue Growth
N/A
22.88
52 Week Low
$55.58
$197.81
52 Week High
$88.46
$495.55

Technical Indicators

Market Signals
Indicator
ADM
ALNY
Relative Strength Index (RSI) 56.43 59.85
Support Level $76.16 $197.81
Resistance Level $84.10 $314.04
Average True Range (ATR) 2.78 10.36
MACD 0.50 5.45
Stochastic Oscillator 73.95 81.94

Price Performance

Historical Comparison
ADM
ALNY

About ADM Archer-Daniels-Midland Company

Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: